Dectrocel, a pioneering health-tech company developing artificial intelligence (AI)-powered diagnostic solutions, has raised Rs 4 crore in recent funding. The round was led by IAN Group-powered BioAngels, with participation from PadUp Ventures and Vinners. Key investors from IAN in this round include Nitin Zamre, Samir Kalia, and Mitesh Shah.
The fresh infusion of capital will be used to scale Dectrocel’s commercial operations across India, enhance its self-learning foundational multimodal AI technology, expand into international markets, and accelerate the launch of its upcoming AI Tools in CT /MRI/PET-CT and Hepato-Pancreatico-Biliary (HPB) diagnostic modules.
Headquartered in Lucknow, Uttar Pradesh, Dectrocel has launched its flagship product, DecXpert, which is one of only three AI-based diagnostic tools approved by the Central Drugs Standard Control Organization (CDSCO) for clinical use in India.
The platform delivers chest X-ray and CT-scan interpretations that are 10 times faster and 98% accurate, addressing India’s acute radiologist shortage - currently at a staggering 1:125,000 doctor-to-patient ratio. This shortage results in diagnosis delays of 7 to 10 days and error rates of up to 40%, particularly in tier-2 and smaller cities where timely intervention can be life-saving.
This funding will enable Dectrocel to expand its commercial deployment of DecXpert across OEM partner networks, penetrate India’s Rs 1,000 crore digital X-ray market, and establish an initial presence in Southeast Asia. The company is also working on product diversification with new diagnostic modules for CT/MRI/ PET-CT scans and HPB disease Modules, and enhancing AI capabilities for broader pathology detection and self-learning adaptability.
